Header Logo

Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.

Nyberg F, Askling J, Berglind N, Franz?n S, Ho M, Holmqvist M, Horne L, Lampl K, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Greenberg JD. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiol Drug Saf. 2015 Nov; 24(11):1121-32.

View in: PubMed